IRCT20170814035697N3
Recruiting
Phase 2
The effect of Olanzapine on chemotherapy induced nausea and vomiting in patients with cancer : A randomized clinical trial
Oroumia University of Medical Sciences0 sites150 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Oroumia University of Medical Sciences
- Enrollment
- 150
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Age over 18 years old.
- •Chemotherapy due to cancer for the first time
Exclusion Criteria
- •Having allergic to olanzapine
- •Patients under Radiotherapy
- •Patients with surgical history
- •Diabetic patients
- •hyperlipidemia
Investigators
Similar Trials
Completed
Phase 3
Olanzapine for Chemotherapy-induced Nausea and Vomiting ProphylaxisComplete Response Rate to Chemotherapy-induced Nausea and Vomiting ProphylaxisNCT04232423Rajavithi Hospital90
Unknown
Phase 4
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung CancerChemotherapy-induced Nausea and VomitingLung CancerNCT03571126Zunyi Medical College156
Not yet recruiting
Not Applicable
Side Effects in Chemotherapy PatientsCTRI/2023/10/059187Sumithra Devadiga
Not yet recruiting
Phase 4
Reduction of the Side Effects during Chemotherapy by Amino AcidsGastrointestinal diseaseJPRN-UMIN000028378Hamamatsu Medical Center80
Active, not recruiting
Phase 1
Study evaluating the effects of chemotherapy on incurable cancer of the esophagus or stomachEsophagogastric adenocarcinomaMedDRA version: 18.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-000127-24-DKRigshospitalet, Department of Oncology98